NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SHUKRAPHAR · data 2026-11-01
Shukra Pharmaceuticals Ltd.
In plain words
Price: 6.3% below its 52-week high of ₹79.88.
Delivery: 27.1% of traded shares were kept for delivery over the last 10 sessions, against 39.6% over the last 53.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹75 cr |
| Net profit (last 12 months) | ₹34 cr |
| Sales growth, 3 years (yearly) | -1.2% |
| Profit growth, 3 years (yearly) | 71.0% |
At a glance
Promoters 51.1%, pledged 0.0%, institutions 0.7%.
P/E 96.6, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 28.9%, ROCE 31.3%, operating margin 57.2%: how much profit it earns on the money it uses.
Debt/equity 0.06, Profit growth 71.0% and sales growth -1.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (28.9%).
- Healthy operating margin (57.2%).
- Profit grew 71.0% a year over 3 years.
- Expensive on earnings (P/E 96.6).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 9/30: Delivery 17.2% over the last 20 sessions vs 35.7% in the 40 before (0.48x); shares delivered per day 1.71x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 7/20: Net +₹2.11 cr bought in bulk/block deals over 90 days (0.03x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend
- 5 Oct 26Deal Bulk deal: HRTI PRIVATE LIMITED bought ₹2.11 cr +17.4% next session
- 21 Sept 26Dividend Dividend ₹0.01 (ex-date) +4.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 |
|---|---|
| Promoters | 51.15% |
| Foreign institutions (FII) | 0.44% |
| Domestic institutions (DII) | 0.22% |
| Mutual funds | 0.00% |
| Retail investors | 7.58% |
| Number of shareholders | 35,007 |
Common questions
How much do promoters hold in Shukra Pharmaceuticals Ltd.?
Promoters held 51.15% of Shukra Pharmaceuticals Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Shukra Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.06, which is very low.
What is Shukra Pharmaceuticals Ltd.'s P/E ratio?
About 96.6, based on the last 12 months' earnings and a price of ₹74.87 (data 2026-11-01).
What is the 52-week high and low of Shukra Pharmaceuticals Ltd.?
The 52-week high is ₹79.88 and the 52-week low is ₹40.06.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals Ltd. | ₹74.87 | ₹3,295 cr | 96.6 | — | 28.9% | 31.3% | 0.06 | +78.1% |
| Aarti Drugs Limited | ₹435.2 | ₹3,977 cr | 20.8 | — | 13.4% | 13.2% | 0.37 | -12.1% |
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
| Unichem Laboratories Limited | ₹483.75 | ₹3,404 cr | 11.2 | — | 9.8% | -0.5% | 0.18 | +3.4% |
| Ind-Swift Laboratories Ltd. | ₹368.2 | ₹3,195 cr | 38.2 | 2.2 | 3.4% | -0.2% | 0.01 | +260.3% |
| Solara Active Pharma Sciences Ltd. | ₹632.6 | ₹3,043 cr | 84.2 | 2.1 | -0.6% | 5.9% | 0.55 | +6.1% |
Compare SHUKRAPHAR with AARTIDRUGS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SHUKRAPHAR in NSE Scanner →